VHH Antibodies

VHH antibodies, also called single-domain antibodies or nanobodies, are the smallest functional fragments of antibodies capable of binding antigens. They originate from the heavy-chain-only antibodies found in camelids such as llamas and camels. Unlike conventional antibodies, which require both heavy and light chains for antigen recognition, VHHs operate as a single domain.

Camelid antibodies are specialized immunoglobulins naturally found in llamas, alpacas, and camels. Unlike conventional antibodies that use both heavy and light chains, camelids produce a unique form known as heavy-chain-only antibodies. Their variable domain, called the VHH or single-domain antibody, retains full antigen-binding activity even without light chains.

Learn about VHH libraries, including their creation, screening methods, structural diversity, and how nanobody technology supports research, diagnostics, and therapeutics.

Camelids provide the origin of VHH antibodies. Biointron highlights their unique biology, how VHHs are developed, and their growing use in diagnostics and therapy.

VHH antibodies offer stability, small size, and strong binding. Biointron highlights their promise in diagnostics, therapeutics, and next-generation antibody design.

VHH antibodies have reshaped biotech. Biointron reviews their discovery, unique advantages, and applications driving innovation in diagnostics and therapeutic development.

Learn about VHH antibodies, their history, diagnostic and therapeutic applications, and their role in advanced platforms like ELISA, biosensors, and targeted medicine.

The alpaca advantage: VHH discovery powered by unique immune repertoires. See how Biointron leverages alpaca libraries for robust nanobody identification.

VHH combine small size with big performance—excellent stability, deep tissue access, and easy formatting—making them powerful tools for research and therapy.